



PRESS RELEASE

Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: integration of the Issuer's statement.

Milan (Italy), June 8th 2020 – With reference to the attention of Consob n. 6 of April 9th, 2020 (http://www.consob.it/documents/46180/46181/ra_20200409_06.pdf/2dd088c5-bff7-48ea-b458-2bdbc431ca06) regarding the inclusion, in the issuer's notice, of an information on the possible impact of the pandemic from COVID-19, on the information required by art. 39, paragraph 1, lett. e) and f) of Consob Regulation no. 11971/1999, in addition to the Issuer's statement approved by MolMed on 29th May 2020 and published on the same date, please refer to the contents of the quarterly report as at 31st March 2020 approved by the board of directors on 11th May 2020 and available on MolMed website. Evaluations therein reported are still to be considered confirmed today.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing its CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.

For further information:

MolMed S.p.A.

Investor Relations & Communication Department

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it